Our Development Pipeline
Timber is strategically building a development pipeline in rare dermatologic diseases that have no approved treatments. Our three core development programs have all received Orphan Drug status. In addition, all of our investigational products have significant market expansion potential into major medical dermatology indications such as acne, port wine stains and tissue scarring. Clinical proof of concept has already been established in two of our mid-stage clinical development programs.
Expanded Access Statement
At this time, Timber does not have an Expanded Access policy. As the development of our programs evolve, we will periodically reassess our policy and post any updates to our website. For more questions, please contact info@timberpharma.com.
TMB-001
TMB-001 (IPEG™ topical isotretinoin) is being developed for the treatment of moderate to severe subtypes of Congenital ichthyosis (CI).
TMB-002
TMB-002 (topical rapamycin) is being developed for the treatment of facial angiofibromas (FA) and tuberous sclerosis complex (TSC).
TMB-003
TMB-003 (topical sitaxentan) is under preclinical evaluation for sclerotic skin diseases.
If you are interested in any of Timber’s ongoing clinical research programs, please contact trials@timberpharma.com.